Pharmaceutical

Novo Nordisk takes a hit as CagriSema underperforms in weight loss

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

Dec 21, 2024 - 06:00
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.
Read the original article

Tags:

Previous Article

FDA approves Ionis’ TRYNGOLZA for FCS treatment

Next Article

FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Record number of respiratory syncytial virus (RSV) designations awarded in 2022

Record number of respiratory syncytial virus (RSV) desi...

Sep 9, 2023

Twist rolls out TCR and CAR libraries for cell therapies development

Twist rolls out TCR and CAR libraries for cell therapie...

Apr 14, 2023

STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access

STAT+: Pharmalittle: U.S. to impose inflation penalties...

Dec 15, 2023